Skip to Content

Fludarabine (Fludara), Cytarabine, Filgrastim (Neupogen), and Idarubicin (Idamycin) (FLAG-Ida)

Treatment Given by Infusion, Treatment Given by Injection

Generic : Fludarabine (floo-DAR-uh-been), Cytarabine (sy-TAYR-uh-been), Filgrastim (fil-GRAS-tim), and Idarubicin (I-duh-ROO-bih-sin)
Brand : Fludara (floo-DARE-uh), Cytosar (sy-ta-SAR), Granix (GRAY-niks), and Idamycin (EYE-duh-muh-sin)
Download In :
Download 0.35MB
Last Update : May 16, 2022

About this Treatment

Fludarabine, Cytarabine, Filgrastim, and Idarubicin regimen is used to treat acute myeloid leukemia (AML).

Disclaimer: Oral Chemotherapy Education (OCE) and Intravenous Cancer Treatment Education (IVE) documents are transitioning to Patient Education Sheets (PES) for consistency and ease of use. Accuracy will be maintained, but updates in formatting and terminology should be expected during this transition. This treatment sheet is under review for PES format.

What are Patient Education Sheets (PES)?

A Patient Education Sheet (PES) is a practical tool created with the unique needs of patients with cancer in mind. Each sheet translates complex treatment information into clear, patient-friendly language. They provide easy-to-follow medication schedules and guidance on managing potential side effects, helping patients and their caregivers feel informed and supported.

These resources are pulled directly by healthcare providers, who can download and print them for distribution during patient visits. This ensures that patients and caregivers leave the clinic with a reliable, easy-to-understand reference tailored to their treatment.

In addition to the standard content, PES documents are also editable in designated sections. Providers can add personalized details such as counseling notes, local resources, or contact information, making each sheet specific to the patient’s care journey.